1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

Size: px
Start display at page:

Download "1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1"

Transcription

1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY 1 Cutting Edge Science 0950 imig Special Keynote Lecture Stem cells 1030 COFFEE CONCURRENT 1A, 1B, 1C Mesothelioma Epidemiology Biomarkers Surgery Symposium 1300 LUNCH 1400 PLENARY 2 - imig medallists session - What have we learnt over the past 50 years? 1530 TEA & POSTERS 1600 CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 Sundowner sessions Genomics Clinical FREE EVENING & IMIG BOARD DINNER 23 Oct Thursday 0830 PLENARY 3 The best of imig COFFEE 1300 LUNCH CONCURRENT 2A, 2B, 2C Combination therapy Nursing Immunology 2 - Clinical trials CONCURRENT 2D, 2E, 2F 1400 Trials in progress: investigators Optimising surgery Optimising Radiotherapy are invited to submit theirs 1530 TEA & POSTERS CONCURRENT 2G, 2H, 2J 1600 Genomics Novel therapeutics: Clinical Pathology Trials Sundowner sessions Biology and biomarkers Chemotherapy have we gone as far as we can go? 1830 on GALA DINNER AND DRUMMING 24 Oct Friday 0830 CONCURRENT 3A, 3B, 3C Social Advocacy Early drug development Personalised therapy 1000 COFFEE 10:30 CONCURRENT 3D, 3E, 3F Animal /Preclinical models Peritoneal mesothelioma Imaging for Mesothelioma 1200 PLENARY 4 CLOSING SESSION All venues are at the Cape Town International Conference Centre CTICC unless otherwise specified

2 DAY 1 WEDNESDAY October REGISTRATION AT CTICC OPENING and WELCOME Presidential Address Opening address by the. Minister of Health South Africa PLENARY 1 Genomics: Tumour Genome Atlas-mesothelioma. An update Mesothelioma--From Chaos to Mitochondrial Functionality. Novel strategies for therapeutic inhibition or What the fractal? 0950 IMIG SPECIAL KEYNOTE LECTURE - Cancer stem cells as a target pathways A 1B 1C COFFEE Epidemiology for Mesothelioma Keynote Presentation Current western mesothelioma epidemics Predicting mesothelioma incidence near Kuruman, South Africa - the MINKS study The South African legacy of asbestos - then and now Mapping environmental asbestos pollution in South Africa Ceramic fiber exposure and Mesothelioma Occasional exposure to asbestos: what is the risk Biomarkers Challenges in development of biomarkers Molecular prognostic factors in practice Pitfalls in biomarker research Surgery Symposium IMIG/IASLC staging The state of the art technique for extrapleural pneumonectomy The state of the art technique for lung-sparing surgery Save the lung or take the lung?-advantages and disadvantages of extrapleural pneumonectomy and pleurectomy decortication Personalising surgery 2

3 LUNCH PLENARY 2 imig medallists - What have we learnt over the past 50 years? Cell lines and animal models Biomarkers and immunotherapy Surgery and other conventional therapies Gene therapy and other novel therapies Understanding signalling events Understanding molecular lesions and events TEA & POSTERS POSTERS - Author stand by posters for discussion with delegates SURGERY: NOVEL THERAPEUTICS: IMAGING AND STAGING: PATHOLOGY AND CYTOLOGY: PROGRAMMATIC APPROACH AND EDUCATIONAL RESOURCES FOR MESOTHELIOMA CARE: D Biology and Pathogenesis Keynote presentation: The BAP1 Cancer Syndrome Suggest PI3K/mTOR Hippo pathway mutations in mesothelioma 1E 1F Multi-Modality Combining chemotherapy and/or radiation with surgery, before, after, never or both: what is the rationale, what is the evidence? Intraoperative adjuvant therapies for malignant pleural mesothelioma -worthwhile or waste of time? Patient selection for multimodality therapy-what is the evidence Immunology 1 Keynote: Let s think outside the box-can we combine surgery and immunotherapy? Should we? How would we? 3

4 Immune microenvironment of mesothelioma Phase I trial of Mesothelin-CAR redirected autologous T cells in human- Checkpoint blockade Dendritic cell treatment results of current studies- What is the place of anti-pd1 treatment in MPM- Discussion SUNDOWNERS 1G 1H Genomics best approaches to understanding molecular lesions. Strengths and pitfalls. How it might inform us about diagnosis, pathogenesis, new pathological categorization and new therapies Clinical topic - FREE EVENING & IMIG BOARD DINNER DAY 2 THURSDAY, October 23 PLENARY 3 - The best of imig the top submitted abstracts (the best abstracts) A 2B COFFEE Combination therapy for Mesothelioma Neo-adjuvant therapy and surgery Changes in FAK and cancer stem cell expression after chemotherapy Novel radiation schedules after surgery Adjuvant therapies after first line treatment Discussion (round table) Nursing Promoting entry into clinical trials & improving access to specialist treatment and care Improving outcomes in Mesothelioma-An international approach to meeting nurses educational needs 4

5 2C Developing and coordinating a specialist mesothelioma program of treatment and care Palliative care in Kuruman-setting up a community oasis Immunology 2 - Clinical trials Keynote Presentation Anti-mesothelin immunotoxin in mesothelioma Phase 2 trial of intrapleural Ad.IFN Anti-CTLA4 checkpoint blockade in patients with mesothelioma Anti CD D LUNCH Trials in progress Investigators are invited to submit their current trials in progress for presentation 2E 2F Optimising surgery P/D the best there is? How to implement surgery in a combined modality approach MARS2 After surgical treatment: A critical appraisal Surgery for MPM - how should we select patients today and how will we select them in five years Optimising Radiotherapy Radioresponsiveness, Rationale, and Roles for Radiation Therapy for Mesothelioma Radiotherapy Techniques and Outcomes After Radical Pleurectomy for Mesothelioma Neoadjuvant Radiation Therapy in Mesothelioma Patients Receiving Extrapleural Pneumonectomy Future Horizons for Radiation Therapy for Mesothelioma: Radiobiology and Immunotherapy TEA & POSTERS POSTERS - Author stand by posters for discussion with delegates DIAGNOSTIC AND PREDICTIVE BIOMARKERS: TRIALS IN PROGRESS POSTER SESSION MULTIMODALITY: 5

6 IMMUNOLOGY: RADIATION THERAPY AND BIOLOGY: G Genomics Keynote presentation:. Tumour suppressors in MPM Genetic targets Genomics and drug sensitivity-r SWAMP study- (UK) 2H Novel therapeutics: Clinical Trials Keynote presentation Novel therapeutics Triple angiokinase inhibition PD-1 Integrating immune checkpoint modulation into therapy for MM FAK 2J Pathology Keynote presentation: Using cytology for MPM diagnosis Cytogenetics for diagnosis Mesobank UK Mesoscape Pathological challenges in diagnosing mesothelioma Clinico-autopsy accuracy in diagnosing asbestos disease SUNDOWNERS 2K 2L Biology and biomarkers How does the biology of MM, especially tumor cell signaling, immunology and tumor microenvironment, inform us about screening, diagnosis, new therapies and disease monitoring Chemotherapy - have we gone about as far as we can go? What is the best way to approach this in the lab and clinic moving forward eg. Mechanisms of chemotherapy resistance? Combined therapies, personalized therapies etc? 1830 on GALA DINNER AND DRUMMING 6

7 A DAY 3 FRIDAY, October 24 Social Advocacy The Global Asbestos Landscape 2014 The critical role scientists and health professionals can play to prevent asbestos-related harm. Recent examples and lessons learned. Limitations of legal recourse in South Africa for mesothelioma victims 3B 3C D Asbestos blues a history of asbestos mining in South Africa Models for early drug development Keynote Presentation- Spheroids and drug sensitivity Primary MPM cultures and multiple drug testing PROOF study: which patient to treat with outcome of primary culture testing) Preclinical molecular pathogenesis of preclinical asbestos induced mesothelioma Towards Personalised therapy Keynote Presentation Human and mouse sequencing data NF2 and FAK-synthetic lethality Targeting NF2 CDKN2A CDKNA and synthetic lethality COFFEE Animal/Preclinical models Keynote Presentation: Spontaneous tumor models in MPM 3E Peritoneal Mesothelioma Keynote Presentation 3F Imaging for Mesothelioma 7

8 1200 PLENARY 4 and CLOSING Closing Session Presentation of Young Investigator & Travel Awards Keynote presentation Closing Remarks and Welcome to imig

EUROPEAN ASSOCIATION FOR CANCER RESEARCH

EUROPEAN ASSOCIATION FOR CANCER RESEARCH STATISTICS REPORT 23 rd Biennial Congress of the EUROPEAN ASSOCIATION FOR CANCER RESEARCH From Basic Research to Personalised Cancer Treatment German Cancer Society Experimental Cancer Research Registration

More information

Patronage requested A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M.

Patronage requested A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M. Patronage requested Faculty A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M. FIGINI (MILAN) J. GALON (PARIS) G. KROEMER (PARIS) M. MAIO (SIENA)

More information

Thank you to our webinar sponsors:

Thank you to our webinar sponsors: Treatment Approaches for Pancreatic Cancer January 27, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll

More information

Cancer Bio-Immunotherapy in Siena - XIth NIBIT Meeting

Cancer Bio-Immunotherapy in Siena - XIth NIBIT Meeting 1 Cancer Bio-Immunotherapy in Siena - XIth NIBIT Meeting Siena - October 17-19, 2013 Scientific Committee: NIBIT Board of Directors Thursday, October 17 12:00 Arrival/Registration/Light lunch 14:00 Welcome

More information

Fukushima Global Medical Science Center

Fukushima Global Medical Science Center Fukushima Medical University Fukushima Global Medical Science Basic Concept Image 2012Digital Earth Technology 2012Cnes/Spot Image DataSIO.NOAA.U.S.Navy.NGA.GEBCO Image 2012GeoEye Google earth Introduction

More information

Institute Agenda San Diego, CA

Institute Agenda San Diego, CA Meeting Room Locations: Meals: General Session Lectures: Study Group A: Study Group B: Study Group C: Study Group D: Study Group E: Study Group F: Institute Agenda San Diego, CA Sunday 2:00pm 3:00pm 3:00pm-3:05pm

More information

BSc Biomedical Sciences

BSc Biomedical Sciences SCHOOL OF HEALTH SCIENCES AND SOCIAL CARE BIOSCIENCES Undergraduate Courses with pathways in: (Biochemistry) (Forensic) (Genetics) (Human Health) (Immunology) All courses available in 3 years full-time

More information

How Will Genomics Change Our Practice? Paula Trahan Rieger RN, MSN, CAE, FAAN CEO, Oncology Nursing Society

How Will Genomics Change Our Practice? Paula Trahan Rieger RN, MSN, CAE, FAAN CEO, Oncology Nursing Society How Will Genomics Change Our Practice? Paula Trahan Rieger RN, MSN, CAE, FAAN CEO, Oncology Nursing Society Objectives Name two possibilities for using information obtained through molecular profiling

More information

INSTITUTE OF MEDICINE WORKSHOP. Workshop Overview

INSTITUTE OF MEDICINE WORKSHOP. Workshop Overview INSTITUTE OF MEDICINE WORKSHOP June 8-9, 2015 The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research Workshop Overview Kastan, MD, PhD Michael B. Duke Cancer

More information

Brain Tumour UK Neuro-oncology Research Centre and brain tumour research at the University of Wolverhampton

Brain Tumour UK Neuro-oncology Research Centre and brain tumour research at the University of Wolverhampton Brain Tumour UK Neuro-oncology Research Centre and brain tumour research at the University of Wolverhampton John Darling and Tracy Warr Brain Tumour UK Neuro-oncology Research Centre University of Wolverhampton

More information

First International Gliomatosis cerebri (GC) group meeting. March 26 27, Paris, France

First International Gliomatosis cerebri (GC) group meeting. March 26 27, Paris, France First International Gliomatosis cerebri (GC) group meeting. March 26 27, 2015. Paris, France Thursday March 26 10:30 am 11:00 am Registration 11:00 am 11:15 am Welcoming: Andres Morales Foundations and

More information

PD-L1 Testing in Non-Small Cell Lung Cancer 2/6/ Mayo Foundation for Medical Education and Research. All rights reserved.

PD-L1 Testing in Non-Small Cell Lung Cancer 2/6/ Mayo Foundation for Medical Education and Research. All rights reserved. PD-L1 Testing in Non-Small Cell Lung Cancer 2/6/2017 1 2 I have nothing to disclose. 3 MPGN Part 1 2/6/2017 As you view this presentation, consider the following important points regarding testing. How

More information

Invited Journal: Nature Medicine. Sponsors: Thermo Fisher. Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain

Invited Journal: Nature Medicine. Sponsors: Thermo Fisher. Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain CNIO Frontiers Meetings Primary and Secondary Brain Tumors 19th 22nd February 2017 Organisers: Richard Gilbertson CRUK Cambridge Institute, UK Michael Weller University Hospital Zurich, Switzerland Massimo

More information

Breast cancer research and a changing treatment pathway

Breast cancer research and a changing treatment pathway Breast cancer research and a changing treatment pathway Stuart McIntosh Clinical Senior Lecturer in Surgical Oncology, QUB Consultant Breast Surgeon, BCH What is the breast surgeon s role in 2016? Surgery

More information

Health Information. Technology and Cancer Information Management. Health Information Technology & Cancer Information Management 333

Health Information. Technology and Cancer Information Management. Health Information Technology & Cancer Information Management 333 Health Information Technology & 333 Health Information Technology and Cancer Information Management Opportunities in the health information field have expanded with changes in health care delivery, utilization

More information

Melanoma information card

Melanoma information card Melanoma statistics Malignant melanoma is estimated to represent 4% of all skin cancers and is responsible for 80% of deaths from skin cancer. (Cancer Research UK, Miller and Mihm, 2006) Cases of skin

More information

Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease

Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/lung-cancer-mtss1-is-a-putativemarker-of-tumour-progression-and-metastatic-disease/ Lung cancer: MTSS1 is a putative marker

More information

RAS mutation testing policy

RAS mutation testing policy RAS mutation testing policy Greater Manchester Cancer Services Colorectal Cancer Pathway Board and Clinical Subgroup Start date: June 2014 Review date: May 2017 RAS mutation testing Background In metastatic

More information

Empowering Personalized Therapy Decisions for Your Patient

Empowering Personalized Therapy Decisions for Your Patient Empowering Personalized Therapy Decisions for Your Patient Colorectal Carcinoma StrandAdvantage Tissue-Specific Genomic Test for Cancer Colorectal tissue-specific genomic test for standard-of-care therapy

More information

6. Tolerance and regulaton

6. Tolerance and regulaton 1 2 Lecture outline Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory receptors

More information

Triple-Negative Breast Cancer Webinar Series Part One: A Medical Update

Triple-Negative Breast Cancer Webinar Series Part One: A Medical Update Triple-Negative Breast Cancer Webinar Series Part One: A Medical Update Rita Nanda, M.D. Assistant Professor of Medicine Co-Director, Breast Medical Oncology Program University of Chicago Medicine April

More information

Biology of Ovarian Cancer

Biology of Ovarian Cancer Biology of Ovarian Cancer Lessons for Treatment Mario Javier Pineda MD/PhD Biology of Ovarian Cancer Key Processes in Human Biology Cell Division Apoptosis Differentiation & Development Lessons for Treatment

More information

PowerPoint Lecture Outlines Reducing Your Risk of Cancer

PowerPoint Lecture Outlines Reducing Your Risk of Cancer PowerPoint Lecture Outlines 13 Reducing Your Risk of Cancer Objectives Define cancer and how it develops. Discuss how lifestyle choices, biological factors, and environmental exposures affect an individual

More information

immunotherapy a guide for the patient

immunotherapy a guide for the patient immunotherapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2 immunotherapy... 5 Monoclonal Antibodies... 6 Vaccines... 7 Adoptive T-Cell Transfer... 8 Oncolytic Viruses...

More information

MELANOMA INSTITUTE AUSTRALIA PATHOLOGY AND STAGING

MELANOMA INSTITUTE AUSTRALIA PATHOLOGY AND STAGING MELANOMA INSTITUTE AUSTRALIA PATHOLOGY AND STAGING PATIENT INFORMATION PATHOLOGY AND STAGING FOR MELANOMA If you have been diagnosed with melanoma, this brochure can provide you with information to help

More information

Utilizing Cell Line Derived and Patient-Derived Xenografts in Humanized NSG Mice

Utilizing Cell Line Derived and Patient-Derived Xenografts in Humanized NSG Mice 3375 Scott Blvd., Suite 18 Santa Clara, CA 9554 USA 28Oct216_v2. Utilizing Cell Line Derived and Patient-Derived Xenografts in Humanized NSG Mice Evaluate human tumor response to immunotherapeutics within

More information

UNIVERSITY OF CHICAGO: TED MULLIN FUND for PEDIATRIC SARCOMA RESEARCH

UNIVERSITY OF CHICAGO: TED MULLIN FUND for PEDIATRIC SARCOMA RESEARCH UNIVERSITY OF CHICAGO: TED MULLIN FUND for PEDIATRIC SARCOMA RESEARCH PREPARED FOR MARY HENRY AND RICK MULLIN AND THE TED MULLIN FUND SEPTEMBER 2011 A decade ago, external funding was not a possibility

More information

Understanding the Biology of Breast Cancer: A Pathologist s Perspective

Understanding the Biology of Breast Cancer: A Pathologist s Perspective Understanding the Biology of Breast Cancer: A Pathologist s Perspective Kimberly H Allison, MD Breast Pathologist Associate Professor of Pathology Stanford University Medical Center GOALS Current understanding

More information

National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team

National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team National Peer Review Measures for the Thoracic Cancers Multidisciplinary Team Project Name: Peer Review Date: 26/05/2014 Release: FINAL Author: Owner: Client: Document Number: Timothy Jackson Cancer Information

More information

Uterine fibroids: Epidemiology, Pathology, and Genetics

Uterine fibroids: Epidemiology, Pathology, and Genetics International Workshop Uterine fibroids: Epidemiology, Pathology, and Genetics organized by: Institute for Medical Genetics, University Medicine Rostock Joern Bullerdiek, Rostock, Germany Thomas Loening,

More information

April Is Cancer Control Month

April Is Cancer Control Month April Is Cancer Control Month What Is Cancer Control? Cancer control month highlights advances in fighting cancer. This includes prevention, early detection, and treatment of cancer. One way to control

More information

The 2016 Northwestern Brain Tumor Institute

The 2016 Northwestern Brain Tumor Institute The 2016 Northwestern Brain Tumor Institute CME Symposium Friday, April 1 Chicago, Illinois 7:15am 3:00 pm Sponsored by Northwestern Medicine Brain cancer is a rare type of cancer, accounting for only

More information

The 2016 Northwestern Brain Tumor Institute

The 2016 Northwestern Brain Tumor Institute The 2016 Northwestern Brain Tumor Institute CME Symposium Friday, April 1 Chicago, Illinois 7:15 am 3:00 pm Sponsored by Northwestern Medicine Brain cancer is a rare type of cancer, accounting for only

More information

International Conference on

International Conference on International Conference on Clinical Sciences and Drug Discovery Nov 2015 02-04 Baltimore USA Tobacco leaf expressing recombinant Factor VIII Red: chloroplasts Green: EGFP co-expressed with recombinant

More information

Jean. Gastrointestinal Cancers Program. p: (203) yalecancercenter.org. smilowcancer.org Yale Cancer Center

Jean. Gastrointestinal Cancers Program. p: (203) yalecancercenter.org. smilowcancer.org Yale Cancer Center INTRODUCTION APPOINTMENTS P ancreatic cancer is a difficult diagnosis that affects over 45,000 people in the United States each year. Thankfully, improved understanding of risk factors for the disease,

More information

P L E U R A L M E S O T H E L I O M A

P L E U R A L M E S O T H E L I O M A For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

More information

First cancer drug developed in Singapore shows encouraging results in early human clinical trials

First cancer drug developed in Singapore shows encouraging results in early human clinical trials 11 March 2011 For immediate release MEDIA RELEASE First cancer drug developed in Singapore shows encouraging results in early human clinical trials National University Cancer Institute, Singapore and the

More information

Early Detection of Lung Cancer by a FISH-based Sputum Test

Early Detection of Lung Cancer by a FISH-based Sputum Test Early Detection of Lung by a FISH-based Sputum Test US Lung Statistic at Glance Estimated New Cases by Sites, 2015 1 Estimated Deaths by Sites, 2015 1 600,000 480,000 360,000 Prostat e 158,040 240,000

More information

Master Online Advanced Oncology

Master Online Advanced Oncology Study part-time team-up internationally! Ulm University is developing an innovative international postgraduate study program Advanced Oncology, addressing clinical oncologists as well as scientists in

More information

Lung Cancer Network Group. Lung Cancer Awareness Month November 2010

Lung Cancer Network Group. Lung Cancer Awareness Month November 2010 Lung Cancer Network Group Lung Cancer Awareness Month November 2010 Lung cancer is the leading cause of cancer related death in the Northern Ireland and the UK 1,2. Each year in Northern Ireland approximately

More information

Lung Cancer. What is lung cancer? Who is at risk for lung cancer?

Lung Cancer. What is lung cancer? Who is at risk for lung cancer? Lung Cancer What is lung cancer? The lungs, a pair of sponge-like, cone-shaped organs, are part of the respiratory system. The right lung has three sections, called lobes; it is a little larger than the

More information

PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS

PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS Primary focus on immuno-oncology www.cgen.com Corporate Overview Ari Krashin Chief Financial and Operating Officer www.cgen.com Jefferies June 2016 1 Safe

More information

Recent Research in Pancreatic Cancer

Recent Research in Pancreatic Cancer Recent Research in Pancreatic Cancer Robert Vonderheide, MD, DPhil Associate Cancer Center Director for Translational Research Abramson Cancer Center University of Pennsylania Philadelphia, PA Clinical

More information

Progress and Controversies in Gynecologic Oncology Conference

Progress and Controversies in Gynecologic Oncology Conference 2016 Progress and Controversies in Gynecologic Oncology Conference 22-23 January 2016 Crowne Plaza Barcelona - Fira Center Barcelona, Spain Welcome On behalf of the co-chairs and Scientific Committee,

More information

Progress in Pancreatic Cancer

Progress in Pancreatic Cancer Progress in Pancreatic Cancer Gina Vaccaro, MD OHSU Medical Oncology September 2014 1 Anatomy of the pancreas DePinho, Nature Reviews, 2002 Pancreatic tumor types Ductal adenocarcinoma (>85%) Acinar cell

More information

Course Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students)

Course Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students) Course Descriptions I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students) This course is offered during the first semester of the second year of the MD Program. It

More information

Genetics and Genomics in Medicine Chapter 10 Questions

Genetics and Genomics in Medicine Chapter 10 Questions Genetics and Genomics in Medicine Chapter 10 Questions Multiple Choice Questions Question 10.1 a) The p53 tumor suppressor regulates the G 2 -M transition in the cell cycle by inhibiting the CDK2-cyclin

More information

Clinical Trials at NIH

Clinical Trials at NIH National Cancer Institute Clinical Trials at NIH in Bethesda, Maryland U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health What is a clinical trial? How do I know if I can participate?

More information

Principles of Cancer Therapy

Principles of Cancer Therapy 1 Principles of Cancer Therapy Professor Mark McKeage Dept of Pharmacology & Clinical Pharmacology The University of Auckland 2 Cancer in New Zealand Cancer is a common clinical problem in NZ 21,050 new

More information

A guide for women who are considering breast cancer treatment with chemotherapy and/or hormonal therapy before surgery

A guide for women who are considering breast cancer treatment with chemotherapy and/or hormonal therapy before surgery A guide for women who are considering breast cancer treatment with chemotherapy and/or hormonal therapy before surgery Contents Introduction... 1 What type of breast cancer do I have?... 2 What treatments

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Section 6» Treatment Radiation Therapy

Section 6» Treatment Radiation Therapy 11 Regional Cancer Report Section 6» Treatment Cancer is not a single disease and cancer treatment decisions are complex. Decisions are made based on the pathology, the patient preference and the latest

More information

ONCOPLASTIC AND RECONSTRUCTIVE SURGERY OF THE BREAST. EIGHT EUROPEAN CONFERENCE BREAST MILANO MEETING BMM 9-12 DECEMBER WEDNESDAY, 9 th DECEMBER

ONCOPLASTIC AND RECONSTRUCTIVE SURGERY OF THE BREAST. EIGHT EUROPEAN CONFERENCE BREAST MILANO MEETING BMM 9-12 DECEMBER WEDNESDAY, 9 th DECEMBER ONCOPLASTIC AND RECONSTRUCTIVE SURGERY OF THE BREAST. EIGHT EUROPEAN CONFERENCE BREAST MILANO MEETING BMM 9-12 DECEMBER 2015 11.00-13.15 REGISTRATION WEDNESDAY, 9 th DECEMBER 13.00-13.15 Welcome and Conference

More information

Phase II Study Design: Examples from A Cancer Cooperative Group Casebook

Phase II Study Design: Examples from A Cancer Cooperative Group Casebook Phase II Study Design: Examples from A Cancer Cooperative Group Casebook Wendy R. Parulekar MD NCIC Clinical Trials Group Queen s University Kingston, On. VANDETANIB in Small Cell Lung Cancer NCIC CTG

More information

8/25/2008 Lung Cancer Gr G e r g e o g r o y r S. Pap a e p, e MD, D FCC FC P C 1

8/25/2008 Lung Cancer Gr G e r g e o g r o y r S. Pap a e p, e MD, D FCC FC P C 1 Lung Cancer Gregory S. Pape, MD, FCCP 1 Introduction Background information Risk factors Pathology Symptoms Diagnostic evaluation Screening Evaluation of a solitary pulmonary nodule (SPN) Treatment Prevention/Smoking

More information

Triple Negative Breast Cancer. Disclosures. Objectives 5/1/2015. Deborah K Walker, DNP, CRNP, AOCN Assistant Professor/Nurse Practitioner

Triple Negative Breast Cancer. Disclosures. Objectives 5/1/2015. Deborah K Walker, DNP, CRNP, AOCN Assistant Professor/Nurse Practitioner Triple Negative Breast Cancer Deborah K Walker, DNP, CRNP, AOCN Assistant Professor/Nurse Practitioner Disclosures I have nothing to disclose in relation to the TNBC presentation. Objectives Improve understanding

More information

Immuno-Oncology: Harnessing the Oncologist That Lies Within A Patient s Immune System

Immuno-Oncology: Harnessing the Oncologist That Lies Within A Patient s Immune System Immuno-Oncology: Harnessing the Oncologist That Lies Within A Patient s Immune System Kevin P. Hubbard, DO, FACOI Interim Chair - Department of Specialty Medicine Professor and Chair - Division of Internal

More information

Triple Negative Breast Cancer, 2014: Expert Perspectives

Triple Negative Breast Cancer, 2014: Expert Perspectives Triple Negative Breast Cancer, 2014: Expert Perspectives A Guide for Patients This guide is based on an expert panel discussion titled "Triple Negative Breast Cancer: Practical Treatment Strategies," developed

More information

Teaming Up Against Sarcoma

Teaming Up Against Sarcoma Teaming Up Against Sarcoma Recorded on: April 4, 2013 Darin Davidson, MD, MHSc, FRCSC Assistant Professor, Department of Orthopaedics and Sports Medicine University of Washington School of Medicine Robin

More information

of Muscle Invasive Bladder Cancer Dr. Christina Canil Medical Oncologist

of Muscle Invasive Bladder Cancer Dr. Christina Canil Medical Oncologist Medical Overview and Treatment of Muscle Invasive Bladder Cancer Dr. Christina Canil Medical Oncologist Disclosures Medical Oncologist Urologists/Radiation Oncologists/Radiologists/Pathologists Nursing

More information

The Role of Gene Therapy in Cancer Treatment. Rehan Mujahid. Abstract

The Role of Gene Therapy in Cancer Treatment. Rehan Mujahid. Abstract The Role of Gene Therapy in Cancer Treatment Rehan Mujahid Abstract Cancer is one of the major diseases in the world. This paper explores the biology of cancer cells and explains how they are originated.

More information

World Class Personalized Cancer Medicine. The Princess Margaret Cancer Centre

World Class Personalized Cancer Medicine. The Princess Margaret Cancer Centre World Class Personalized Cancer Medicine The Princess Margaret Cancer Centre Strategy 2013-2018 Contents 4 The Princess Margaret Cancer Centre 6 Accountability 7 Our Resources snd Activity 8 Research

More information

Immune Therapy for Pancreatic Cancer

Immune Therapy for Pancreatic Cancer Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:

More information

From Preclinical Drug Development to Clinical Application. Exploring Novel Therapeutic Strategies Using the Plant Derived Polyphenol Curcumin

From Preclinical Drug Development to Clinical Application. Exploring Novel Therapeutic Strategies Using the Plant Derived Polyphenol Curcumin From Preclinical Drug Development to Clinical Application Exploring Novel Therapeutic Strategies Using the Plant Derived Polyphenol Curcumin PD Dr. Beatrice E. Bachmeier Inst. of Laboratory Medicine Ludwig-Maximilians-University

More information

San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium Tuesday, December 8, EDUCATION SESSIONS 12:35 p.m. Careers in Translational Research Geoffrey Shapiro, MD, PhD Director, Early Drug Development Center Clinical Director, Center for DNA Damage and Repair

More information

TP53 and Cancer. Terrence Wong. Cancer Biology Pathway 03/08/2016

TP53 and Cancer. Terrence Wong. Cancer Biology Pathway 03/08/2016 TP53 and Cancer Terrence Wong Cancer Biology Pathway 03/08/2016 Outline 1. Background into TP53 and the role TP53 mutations play in cancer 2. Role of TP53 mutations in the evolution of hematopoietic populations

More information

This vision does not represent government policy but provides useful insight into how brain & CNS cancer services might develop over the next 5 years

This vision does not represent government policy but provides useful insight into how brain & CNS cancer services might develop over the next 5 years Brain & CNS cancers 2015 Annex B Epidemiology 1. The incidence of brain & CNS tumours in England was reported to be just under 4,000 in 2007. 1 This is expected to increase further with an aging population

More information

Important to Know. The Basics

Important to Know. The Basics Important to Know The American Board of Obstetrics and Gynecology (ABOG) recommend gynecologic oncologists as the premier resource for women fighting gynecologic malignancies. Statistics show working with

More information

Delivering the right treatments, at the right time, every time, to the right person

Delivering the right treatments, at the right time, every time, to the right person Delivering the right treatments, at the right time, every time, to the right person Barack Obama NEW PRECISION ONCOLOGY TEST TO IDENTIFY THE MOST EFFECTIVE ANTI-CANCER TREATMENT Patient Guide 2 3 Applicable

More information

BIOMEDICAL SCIENCE: A COURSE THAT COUNTS

BIOMEDICAL SCIENCE: A COURSE THAT COUNTS BIOMEDICAL SCIENCE: A COURSE THAT COUNTS Department of Pharmacy, Health and Well-being Why study Biomedical at Sunderland? By studying Biomedical at Sunderland, you are choosing to put your future career

More information

The challenges of the different stakeholders An academic perspective

The challenges of the different stakeholders An academic perspective The challenges of the different stakeholders An academic perspective Heinz Zwierzina, M.D. CDDF Early Clinical Trial Unit Innsbruck Medical University The challenge (level 1) D. Hanahan and R. A. Weinberg,

More information

Medical Coverage Policy Immunoassay for Tumor Antigens

Medical Coverage Policy Immunoassay for Tumor Antigens Medical Coverage Policy Immunoassay for Tumor Antigens Device/Equipment Drug Medical Surgery Test Other Effective Date: 7/1/2011 Policy Last Updated: 5/7/2013 Prospective review is recommended/required.

More information

Targeted therapies for Early Stage Breast Cancer. Cynthia Vakhariya D.O. Providence Hospital

Targeted therapies for Early Stage Breast Cancer. Cynthia Vakhariya D.O. Providence Hospital Targeted therapies for Early Stage Breast Cancer Cynthia Vakhariya D.O. Providence Hospital Case 55-year-old postmenopausal woman Routine screening mammogram 3 cm irreg mass in L breast Left breast ultrasound

More information

PRELIMINARY PROGRAM (Version ) The 36 th Meeting of the Scandinavian Sarcoma Group. Helsinki. Map of conference venue

PRELIMINARY PROGRAM (Version ) The 36 th Meeting of the Scandinavian Sarcoma Group. Helsinki. Map of conference venue PRELIMINARY PROGRAM (Version 2012-07-03) Map of conference venue The 36 th Meeting of the Scandinavian Sarcoma Group Helsinki Scandinavian Sarcoma Group 1979 Date: October 9-11, 2013 Place: Hotel Crowne

More information

Welcome and Introductions

Welcome and Introductions Clinical Trials or Standard Treatment? Understanding Options for Blood Cancers Welcome and Introductions Clinical Trials or Standard Treatment? Understanding Options for Blood Cancers John P. Leonard,

More information

Careers in Haematology

Careers in Haematology Careers in Haematology A Guide for Medical Students and Junior Doctors Haematology is the medical speciality concerned with blood disorders. Your non-medical friends however will always think that you

More information

BREAST CANCER FALL UPDATE CURRENT CONTROVERSIES 2014

BREAST CANCER FALL UPDATE CURRENT CONTROVERSIES 2014 Surgical Oncology Network BREAST CANCER FALL UPDATE CURRENT CONTROVERSIES 2014 IN PARTNERSHIP WITH: BC CANCER AGENCY UBC DEPARTMENT OF SURGERY THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA SATURDAY

More information

KEY MESSAGES. Of the cases diagnosed in 2003, 33.6% were women between 40 and 49 years of age.

KEY MESSAGES. Of the cases diagnosed in 2003, 33.6% were women between 40 and 49 years of age. KEY MESSAGES Breast cancer is the commonest cancer in all ethnic groups and in all age groups in females from the age of 15 years onwards. The overall Age-Standardised Incidence Rate (ASR) was 39.3 per

More information

Tuesday, March 17, Wednesday, March 18, 2015

Tuesday, March 17, Wednesday, March 18, 2015 KEY: PRE CONFERENCE SYMPOSIUM Sponsored Symposium Symposium Plenary Lecture Other Event *Pre-registration is required for the Informal Networking with Professor Lunch Session Tuesday, March 17, 2015 Hermes

More information

Highlights from the 17th Annual IASLC World Conference on Lung Cancer: International Focus on Emerging Advances in NSCLC Management

Highlights from the 17th Annual IASLC World Conference on Lung Cancer: International Focus on Emerging Advances in NSCLC Management Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

THE BREAST COURSE 2013

THE BREAST COURSE 2013 THE BREAST COURSE 2013 Learning objectives At the end of The Breast Course, the participant should be able to: 1. Explain the major pathologies affecting the breast; 2. Explain existing, novel and state-of-the-art

More information

Chapter 2: Neoplasms

Chapter 2: Neoplasms Primary malignant neoplasms overlapping site boundaries Listed Malignant neoplasm of ectopic tissue GENERAL GUIDELINES: Primary malignant neoplasms overlapping site boundaries A primary malignant neoplasm

More information

Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC

Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC Rare disease research in FP7, Outlook in Horizon 2020, IRDiRC Dr. Iiro Eerola Scientific Project Officer Unit for Personalised Medicine Directorate F Health DG Research and European Commission iiro.eerola@ec.europa.eu

More information

Medical statistics. Lecture 2: Types of medical studies. Krista Fischer

Medical statistics. Lecture 2: Types of medical studies. Krista Fischer Medical statistics Lecture 2: Types of medical studies. Krista Fischer The evidence pyramid Motivated by: http://library.downstate.edu/ebm/2100.htm Clinical research, providing results that are relevant

More information

ROTATION SUMMARY ONCOLOGY WARD

ROTATION SUMMARY ONCOLOGY WARD ROTATION SUMMARY ONCOLOGY WARD Rotation Contacts and Scheduling Details Rotation Director: Clare Twist, M.D. Clare.twist@stanford.edu 723-5535 Introduction The LPCH Oncology Rotation is designed to increase

More information

Published. Website. Behalf Of. 1 Acta Haematologica. 2 American Journal of Hematology. 3 Annals of Hematology

Published. Website. Behalf Of. 1 Acta Haematologica. 2 American Journal of Hematology. 3 Annals of Hematology 1 Acta Haematologica This journal includes coverage of current hematology research. All manuscripts are subject to editorial review. Manuscripts intended for rapid communication must present new findings

More information

Genomics: Personalized Medicine in Brain Cancer?

Genomics: Personalized Medicine in Brain Cancer? Genomics: Personalized Medicine in Brain Cancer? Stephen Shiao MD, PhD Assistant Professor Cedars-Sinai Medical Center Department of Radiation Oncology What is genomics? 2 The relationship between DNA,

More information

Metastatic Cancer: Questions and Answers. Key Points

Metastatic Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Metastatic Cancer: Questions

More information

Specific Basic Standards for Osteopathic Fellowship Training in Hematology/Oncology INSPECTION CROSSWALK

Specific Basic Standards for Osteopathic Fellowship Training in Hematology/Oncology INSPECTION CROSSWALK Specific Basic Standards for Osteopathic Fellowship Training in Hematology/Oncology INSPECTION CROSSWALK Instructions Program: Program Number: Date: Site er: Page 2 of 63 er), 2 or 3 Not Not IV. INSTITUTIONAL

More information

Oncology & Cancer Science

Oncology & Cancer Science June 12-14, 2017 Sydney, Australia International Conference on Oncology & Cancer Science Theme: Cancer Research towards contemporary therapeutics and restorative approaches International conference on

More information

PRELIMINARY PROGRAM. Hotel Le Saint-Paul NICE, FRANCE. International Mouse Models of Skin Cancer symposium.

PRELIMINARY PROGRAM. Hotel Le Saint-Paul NICE, FRANCE. International Mouse Models of Skin Cancer symposium. PRELIMINARY PROGRAM www.canceropole-paca.fr EDITORIAL Skin cancer is a widely spread disease, which causes patient death and arises from both epithelial and nonepithelial cells. Deciphering the molecular

More information

TUMOR-SPECIFIC GOALS AND OBJECTIVES

TUMOR-SPECIFIC GOALS AND OBJECTIVES TUMOR-SPECIFIC GOALS AND OBJECTIVES Breast Goal: Be able to discuss the natural history of breast cancer. Objective: Resident will orally demonstrate knowledge of the disease to attending faculty in terms

More information

A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e

A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e VOLUME II A m e r i C A n A C A d e m y o f A N T I - A G i n G M e d i c i n e Established in 1992 www.worldhealth.net Fellowship in Integrative Cancer Therapy The American Academy of Anti-aging Medicine

More information

Fundraising and Research Objectives

Fundraising and Research Objectives THE EHE FOUNDATION THE EHE RARE CANCER CHARITY (UK)* THE EHE RARE CANCER FOUNDATION (AUSTRALIA)* Fundraising and Research Objectives Thank you for taking the time to find and engage with our Fundraising

More information

PRELIMINARY PROGRAM (Version 2013-01-22) The 36 th Meeting of the Scandinavian Sarcoma Group

PRELIMINARY PROGRAM (Version 2013-01-22) The 36 th Meeting of the Scandinavian Sarcoma Group PRELIMINARY PROGRAM (Version 2013-01-22) The 36 th Meeting of the Scandinavian Sarcoma Group Helsinki Date: October 9-11, 2013 Place: Hotel Crowne Plaza Mannerheimentie 50 Helsinki 00260 Finland Hotel

More information

High Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem

High Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem High Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem rmerrell@northshore.org Objectives Provide updates on

More information

Overview of Research from the Centre for Cancer Research & Cell Biology, Queen s University Belfast. Kevin M. Prise

Overview of Research from the Centre for Cancer Research & Cell Biology, Queen s University Belfast. Kevin M. Prise Overview of Research from the Centre for Cancer Research & Cell Biology, Queen s University Belfast Kevin M. Prise Centre for Cancer Research and Cell Biology (CCRCB) www.qub.ac.uk/ccrcb CCRCB Northern

More information

Malignant Lesions in Kids: Ewing s Sarcoma and Osteosarcoma. Marco Vennettilli PGY 3 Sept 26, 2007

Malignant Lesions in Kids: Ewing s Sarcoma and Osteosarcoma. Marco Vennettilli PGY 3 Sept 26, 2007 Malignant Lesions in Kids: Ewing s Sarcoma and Osteosarcoma Marco Vennettilli PGY 3 Sept 26, 2007 Outline Presentation Radiology Histology Genetics Treatment and Outcomes Ewing Sarcoma First described

More information

Transcript. Study Types in Epidemiology. Study Types in Epidemiology. About this Module. Objectives

Transcript. Study Types in Epidemiology. Study Types in Epidemiology. About this Module. Objectives Study Types in Epidemiology Welcome to Study Types in Epidemiology. My name is John Kobayashi. I m on the Clinical Faculty at the, at the School of Public Health and Community Medicine, University of Washington

More information